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Background
 
Each year more than 220,000 Medi-
care beneficiaries receive care from hospice pro-
grams designed to enhance the quality of the end of 
life. Enrollment requires certification by a physician 
that the patient has a life expectancy of less than six 
months. We examined how long before death pa-
tients enrolled in hospice programs.
 
Methods
 
Using 1990 Medicare claims data, we an-
alyzed the characteristics and survival of 6451 hos-
pice patients followed for a minimum of 27 months 
with respect to mortality.
 
Results
 
The patients’ mean age was 76.4 years; 
92.4 percent were white. Half the patients were 
women, and 80.2 percent had cancer of some type. 
The most common diagnoses were lung cancer 
(21.4 percent), colorectal cancer (10.5 percent), and 
prostate cancer (7.4 percent). The median survival 
after enrollment was only 36 days, and 15.6 percent 
of the patients died within 7 days. At the other ex-
treme, 14.9 percent of the patients lived longer than 
six months. Survival varied substantially according 
to diagnosis, even after adjustment for age and co-
existing conditions. The unadjusted survival after 
enrollment was shortest for those with renal failure, 
those with leukemia or lymphoma, and those with 
liver or biliary cancer; it was longest for those with 
chronic lung disease, those with dementia, and 
those with breast cancer. Patients at for-profit, larger, 
outpatient, or newer hospices lived longer after en-
rollment than those in other types of hospice pro-
grams.
 
Conclusions
 
Most patients who enter hospice care 
do so late in the course of their terminal illnesses. The 
timing of enrollment in hospice programs varies sub-
stantially with the characteristics of the patients and 
the hospices. (N Engl J Med 1996;335:172-8.)
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HE primary goal of hospice care is the pal-
liation of patients’ physical and mental suf-
fering. Hospice care may offer several ad-
vantages over traditional, hospital-based care
for people with terminal illnesses. It can be delivered
in a patient’s home, allowing death to take place at
home,
 
1,2 
 
and it may optimize the relief of pain,
 
3 
 
in-
crease patients’ satisfaction,
 
4-6 
 
and increase cost ef-
T
 
fectiveness.
 
7-12 
 
Partly in anticipation of such advan-
tages, Medicare began covering hospice care for its
beneficiaries in 1982.
 
13,14 
 
A Medicare beneficiary with
a  terminal  illness  who  elects  hospice  care  receives
noncurative  medical  and  support  services,  many  of
which would not otherwise be covered. These serv-
ices include nursing care; physicians’ services; medi-
cal appliances; drugs; short-term hospitalization; the
services of homemakers and home health aides; phys-
ical, occupational, and speech therapy; psychologi-
cal counseling; and social services. About 80 percent
of  patients  have  these  services  provided  in  their
homes.
 
15 
 
In 1994, a total of 221,849 beneficiaries re-
ceived hospice care at a cost to Medicare of $1.32 bil-
lion, and the number of beneficiaries receiving hos-
pice care has been growing at an annual rate of 10 to
20 percent (Bureau of Policy Development, Health
Care  Financing  Administration:  unpublished  data).
Medicare beneficiaries make up approximately 80 per-
cent of all patients receiving hospice care in the Unit-
ed States.
 
16 
 
Under Medicare regulations, a beneficiary is eligi-
ble for coverage of hospice care only if the patient’s
doctor and the medical director of the hospice certify
that the patient is “terminally ill,” defined as having a
life expectancy of six months or less.
 
17 
 
By electing to
receive hospice care, the beneficiary waives all rights to
Medicare payment for curative treatment of his or her
terminal condition. The six-month standard may be
difficult, however, for physicians to interpret or ap-
ply.
 
18 
 
Using a multistate sample, we determined the
characteristics of Medicare patients whose life expect-
ancy  had  been  predicted  and  who  had  enrolled  in
hospice programs. We also examined the duration of
their survival after enrollment.
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METHODS
 
Sources of Data
 
From the Health Care Financing Administration, we obtained
the Standard Analytic File (SAF) for all Medicare patients admit-
ted to hospice programs during 1990 in California, Florida, New
York, Pennsylvania, and Texas. These five states accounted for 27
percent of all Medicare-certified hospice programs (320 provid-
ers) and approximately 36 percent of all Medicare beneficiaries in
1990. Additional data were obtained from 1990 Medicare Pro-
vider Analysis and Review (MEDPAR) files; vital-status files con-
taining dates of death for beneficiaries who had died; and Provid-
er of Services (POS) files describing the hospices.
 
The Cohort
 
The study cohort consisted of the 6451 adults who were en-
rolled for the first time in their lives in a hospice program (cov-
ered by Medicare) between October 1 and December 31, 1990,
in the five states. Using the vital-status files, we obtained follow-
up with respect to mortality through April 1, 1993 (a minimum
of 27 months of follow-up from the date of enrollment). On this
date, only 273 patients (4.2 percent of the cohort) were still alive.
For each patient in the cohort, we also obtained data regarding
prior inpatient hospitalizations and calculated a score on the Charl-
son  comorbidity  index
 
19
 
  using  information  from  the  MEDPAR
files about hospitalizations during the 270 days before admission
to a hospice.
 
 
 
Finally, we obtained information on the characteristics
of the hospice program from the POS file.
 
Statistical Analysis
 
We  estimated  survival  in  the  cohort  with  the  Kaplan–Meier
method.
 
20 
 
In  assessing  the  relation  between  diagnosis  and  the
length of survival after enrollment in a hospice, we used Tukey
box plots, which show the median, interquartile range (the range
from the 25th to the 75th percentile for values in the cohort),
and “whiskers” for each variable (whiskers are 1.5 times the in-
terquartile range and spread out from the first and third quartiles;
by definition, they cannot extend beyond the smallest or largest
observed value).
 
21 
 
We performed Cox regression analyses to assess the association
between  diagnosis  and  survival  while  controlling  for  potential
confounders and to examine the importance of other variables. In
Cox regression, the association between a variable and survival is
expressed as a hazard rate or risk ratio, similar to an odds ratio.
 
22
 
In this study a risk ratio greater than 1.0 was associated with a
higher risk of death and therefore with a shorter survival after en-
rollment in a hospice, and a ratio less than 1.0 indicated a lower
risk of death and longer survival.
The dependent variable in our analyses was the length of sur-
vival in days. The independent variables included the patient’s age,
sex, race, and principal diagnosis (defined as the condition report-
ed in the SAF to be the cause of the patient’s admission, indicated
by codes from the 
 
International Classification of Diseases, 9th Re-
vision, Clinical Modification
 
23
 
). We grouped principal diagnoses
into 19 categories, as shown in Table 1. Our taxonomic system
reflected both clinical considerations about the similarity of dis-
eases and numerical considerations to ensure that no one catego-
ry was too large or too small for analysis. Patients with missing data
on race were excluded from the regression analysis (n
 
 
 
166). No
data were missing for any of the other variables, except as out-
lined below for the Charlson score.
We used the MEDPAR data from the patients’ hospital stays in
the preceding 270 days to develop a Charlson comorbidity score
for every patient.
 
24 
 
This score ranges from 0 to a theoretical max-
imum of 33 and is based on the presence of certain diseases with
assigned values. We also developed an adjusted Charlson score,
which excluded the patient’s primary diagnosis at the time of ad-
mission to a hospice, since our intention was to measure and con-
trol for the effects of conditions other than the patient’s principal
diagnosis. There were 1545 patients in the cohort (24.0 percent)
who were not hospitalized in the 270 days before their admission
to a hospice program; it was thus not possible to assign them a
Charlson score. We dealt with these missing values by substituting
the mean Charlson score for the patient group as a whole and in-
cluding a dummy variable representing missing data among the
explanatory variables in the regression model.
 
25 
 
The coefficient
for this missing-data variable may be interpreted as the effect of
having had no recent hospitalizations.
We developed three measures of the use of resources before ad-
mission to the hospice: the number of hospitalizations in the 270
days before enrollment; the total number of hospital days in the
270-day period; and the total number of hospital days in the 30
days before enrollment. 
Finally,  we  developed  four  variables  to  describe  the  hospice
providers: the number of years the program had been in opera-
tion as a Medicare provider as of 1990 (range, 1 to 8); the num-
ber of employees (“large” hospices were those with 30 or more
employees); the type of provider (“inpatient,” defined as a pro-
gram run by a hospital or by an inpatient nursing facility, or “out-
patient,” defined as a program run by a dedicated hospice or by a
home health agency); and the type of ownership (for-profit, pro-
prietary vs. nonprofit, voluntary or government).
 
RESULTS
 
Characteristics of Medicare Beneficiaries in Hospice Care
 
The mean (
 
 
 
SD) age of the patients in the cohort
was  76.4
 
 
 
9.0  years;  92.4  percent  of  the  patients
were white, and 50.0 percent were women. Approx-
imately half the patients in the cohort (49.7 percent)
were cared for by large hospices; 16.1 percent by for-
profit hospices; and 22.8 percent at inpatient hos-
pice programs. Of the patients in the cohort, 80.2
percent had cancer of some type; lung cancer (21.4
percent), colorectal cancer (10.5 percent), and pros-
tate cancer (7.4 percent) were the most common di-
agnoses (Table 1). The patients were very sick; the
mean unadjusted score on the Charlson index for
the 4906 patients for whom this score could be de-
termined was 5.2
 
 
 
3.3, and the mean adjusted Charl-
son score was 3.8
 
 
 
3.0.
In the 270 days before admission to a hospice pro-
gram, the patients averaged 1.6
 
 
 
1.7 hospital admis-
sions; only 1545 patients (24.0 percent) had no ad-
missions during that 270-day period. The mean total
number of hospital days in the 270 days before en-
rollment in a hospice program was 18.3
 
 
 
23.3; 1296
(20.0 percent) of the patients spent more than 30 of
the 270 days as hospital inpatients. The mean total
number of hospital days in the 30 days before enroll-
ment in a hospice program was 11.5
 
 
 
13.7. Of the co-
hort, 1814 patients (28.1 percent) were not hospital-
ized for any part of the 30 days before entering a
hospice program; 2942 patients (45.6 percent) were
hospitalized for at least part of the 30 days before en-
rollment; and 1695 patients (26.3 percent) spent the
whole month in the hospital. The median lengths of
survival  after  enrollment  in  a  hospice  program  for
these  three  groups  were  43  days,  32  days,  and  26
days, respectively (P
 
 
 
0.01 by the Kruskal–Wallis test
of the difference in medians among groups).
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Survival after Enrollment in a Hospice Program
 
The  median  length  of  survival  after  enrollment
was 36 days (interquartile range, 12 to 97) (Fig. 1).
A substantial minority of patients, 15.6 percent, died
within 7 days of enrollment, and 28.5 percent died
within 14 days. At the other extreme, 14.9 percent
lived longer than 180 days, and 8.2 percent lived
longer than a year. The patients who lived more than
a year after enrollment were more likely than those
who died sooner to have one of several diagnoses:
cancer  of  the  female  genital  tract,  breast  cancer,
stroke, congestive heart failure, dementia, and chron-
ic obstructive pulmonary disease.
 
Disease-Specific Survival
 
There was substantial variation in both the medi-
an length of survival and in the range of survival
times according to diagnosis (Fig. 2 and Table 1).
The median length of survival varied from 17 days
for patients with renal failure to 77 days for those
with chronic obstructive pulmonary disease (P
 
 
 
0.001
by the Kruskal–Wallis test of the difference in medi-
ans among diagnostic groups) (Table 1). The inter-
quartile range varied from 39 days for liver or biliary
cancer to 349 days for dementia (P
 
 
 
0.001 by Bart-
lett’s test of the difference in the range among diag-
noses) (Fig. 2). The proportion of patients who died
within a week varied from 7.1 percent for those with
cancer of the central nervous system to 29.4 percent
for those with renal failure; the proportion of pa-
tients who died more than six months after enroll-
ment varied from 8.8 percent for liver or biliary can-
cer to 34.7 percent for dementia (Table 1).
The variability of the length of survival among pa-
tients with different diagnoses persisted after we con-
trolled  for  measured  characteristics  of  the  patients
and the hospice providers (Table 2). Specifically, as
compared with patients with lung cancer, and with
adjustment  for  other  factors,  patients  with  breast
cancer had an 18 percent lower risk of death (hence,
longer survival after enrollment), those with central
nervous system cancer a 17 percent lower risk, those
with prostate cancer a 15 percent lower risk, those
with congestive heart failure a 24 percent lower risk,
those  with  dementia  a  29  percent  lower  risk,  and
those with chronic obstructive pulmonary disease a
29 percent lower risk. Conversely, those with liver or
biliary cancer had a 24 percent higher risk of death
(hence, shorter survival) than those with lung cancer.
A joint test of significance for the variables related to
the primary diagnosis provides evidence of the im-
portance of the diagnosis in determining the length
of survival after enrollment (P
 
 
 
0.001).
 
Other Factors Associated with Survival
 
Additional findings in the regression analysis were
that  men  had  a  10  percent  higher  risk  of  death
(indicating shorter survival) than women, and whites
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Cancer
 
Leukemia or lymphoma
Urinary tract
Colon or rectum
Pancreas
Female genital tract
Upper gastrointestinal tract
Head or neck
Lung
Breast
Central nervous system
Prostate
Liver or biliary tract
All other cancers
291 (4.5)
256 (4.0)
678 (10.5)
289 (4.5)
223 (3.5)
221 (3.4)
101 (1.6)
1378 (21.4)
364 (5.6)
141 (2.2)
480 (7.4)
205 (3.2)
548 (8.5)
23.0
24.0
31.0
31.0
34.0
34.5
38.0
38.0
43.5
44.0
46.0
50.0
32.5
20.6
14.1
15.8
18.3
17.5
13.1
17.8
14.2
13.5
7.1
14.0
22.4
15.1
14.1
12.9
12.4
10.0
14.8
9.0
13.9
11.8
9.0
14.2
13.7
8.8
12.0
 
Other diseases
 
Renal failure
Stroke
Congestive heart failure
Dementia
Chronic obstructive pulmonary disease
All other noncancer diseases
85 (1.3)
142 (2.2)
316 (4.9)
95 (1.5)
200 (3.1)
438 (6.8)
17.0
33.0
43.5
74.0
76.5
34.0
29.4
21.1
14.2
9.5
12.0
18.3
12.9
22.5
22.5
34.7
32.0
21.2
 
Total
 
6451 (100.0) 36.0 15.6 14.9
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had an 11 percent higher risk than nonwhites (Ta-
ble  2).  In  terms  of  time,  the  unadjusted  median
length of survival was 33.5 days for men as com-
pared  with  39  days  for  women,  and  34  days  for
whites as compared with 38 days for nonwhites. Af-
ter we controlled for other factors, age was not as-
sociated with the length of survival after enrollment
in a hospice. Each point on the adjusted Charlson
index was associated with a 3 percent higher risk of
death. Patients cared for by large hospices had a 23
percent lower risk of death than others, those in for-
profit hospices a 10 percent lower risk of death, and
those in inpatient facilities a 14 percent higher risk of
death. The unadjusted median length of survival was
46 days in large hospices as compared with 28 days
in small hospices, 52 days in for-profit hospices as
compared  with  32  days  in  not-for-profit  hospices,
and 39 days in outpatient facilities as compared with
26 days in inpatient facilities.
 
DISCUSSION
 
In our study of survival among Medicare patients
enrolled in hospice programs, four facts were evi-
dent. First, overall survival was short, with a median
of 36 days. Second, there was substantial variation
in the length of survival after enrollment; many pa-
tients survived for short periods (less than 7 days)
and many for long periods (more than 180 days),
together accounting for 30.5 percent of all patients.
Third,  there  was  substantial  variation  in  both  the
median survival and the range of survival times ac-
cording to diagnosis. Fourth, there was substantial
variation in survival according to the type of hospice
provider, even after adjustment for a number of char-
acteristics of the patients.
Previous  studies  of  single  hospices,  both  in  the
United States and abroad, have found median sur-
vival times of 11 to 30 days,
 
26-33
 
 and those based on
data from multiple hospices have found survival times
of 25 to 35 days.
 
3,10,34 
 
These studies have been lim-
ited, however, by their focus on inpatients, by their
exclusion of patients with diagnoses other than can-
cer,  or  by  their  incomplete  or  short  follow-up  or
small or nonrepresentative samples. Moreover, previ-
ous studies of survival among patients in hospices ei-
ther have neglected the role of diagnosis
 
33 
 
or have
not  found  a  relation  between  diagnosis  and  the
length of survival after enrollment
 
34
 
; some studies,
however, have suggested a relation between certain
diagnoses and the timing of patients’ referral to hos-
pices.
 
29,35
 
The duration of survival after enrollment in a hos-
pice is an important outcome to measure because it
is relevant to the quality and cost of care that patients
receive at the end of life. Both long and short survival
— especially to the extent that the length of survival
may be due to avoidably early or late enrollment —
may have adverse economic consequences for payers
and cause needless suffering for patients.
 
3,29,36
 
 For ex-
ample, for many patients, short survival after enroll-
ment in a hospice program may mean that they have
made inadequate use of a desirable type of terminal
care and that their hospice providers have had inad-
equate time to learn their needs and develop an op-
timal plan for care. Short survival might also mean
that patients have received costly and possibly un-
necessarily aggressive care for an unduly long period
before enrollment in the hospice. Although patients
may have derived benefit from short stays in hospices
in some cases, earlier referral, to the extent that it was
possible, might have brought even greater benefits.
The timing of enrollment, an event that is under
the control of human decision makers, is the funda-
mental determinant of the observed duration of sur-
vival  in  hospices.  Although  patients,  families,  and
the hospice staff members influence decisions about
enrollment,
 
7
 
 physicians are critical to this process.
Physicians act as gatekeepers, initiate the great ma-
jority of referrals, and are required to certify that the
patient has a life expectancy of less than six months.
Consequently, it might be possible to modify the sur-
vival curve of patients enrolled in hospices by chang-
ing the behavior of patients, physicians, or hospice
providers. If patients were enrolled earlier and if ef-
forts were directed to reducing the percentages of
patients with especially long or short stays in hospic-
es, it might be possible to improve the use of hospice
care from both the individual and the social perspec-
tives.
Our  data  demonstrate  that  the  majority  of  pa-
tients enrolled in hospice programs under the Medi-
care hospice benefit, especially those with cancer, are
enrolled relatively late in the course of a terminal ill-
ness. Several factors may be responsible for this fact.
 
Figure 1. 
 
Kaplan–Meier Survival Curve for 6451 Medicare Ben-
eficiaries Enrolled in Hospice Programs in 1990.
Survival was measured from the day of enrollment in the hos-
pice program to the day of death.
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For example, patients may resist being told that the
illness is terminal, and physicians may want to pre-
serve hope by postponing referral. The difficulty phy-
sicians face in making prognoses probably also has a
role. Commentators have noted that physicians typ-
ically make poor judgments about survival in termi-
nally ill patients; both unduly pessimistic prognoses
(with consequent early referral to hospices) and un-
duly optimistic prognoses (with late referral) may have
adverse effects.
 
37-39
 
 Unfortunately, few studies have ex-
amined the process of prognostication in patients in
hospice
 
40,41
 
 or hospital
 
42 
 
settings.
Current  Medicare  regulations  may  inadvertently
reinforce the late enrollment of patients by specify-
ing an upper limit to survival — that is, by stating
only patients with less than six months to live are to
be referred. However, the fact that short survival at
hospices  is  also  seen  in  countries  other  than  the
United States,
 
28,31-33
 
 where there are different regu-
lations, suggests the importance of more fundamen-
tal  factors  related  to  how  physicians  and  patients
confront terminal illness and make predictions about
survival. Nevertheless, alternative prognostic stand-
ards, such as requiring that the prognosis be “an av-
erage survival of six months” or “a 50 percent prob-
ability of death in three months,” might minimize the
possible contribution of Medicare regulations to late
enrollment.
Enrolling patients earlier, especially those other-
wise destined to have short stays, might enhance the
quality of end-of-life care and also prove cost effec-
tive.  Although  an  increase  in  the  median  survival
due to earlier enrollment would increase the costs to
Medicare of hospice care, it might nevertheless be
cost  saving  if  expensive  in-hospital  care  were  sup-
planted. Of the total hospital days in the 270 days
before enrollment, 63 percent were during the 30
days just before admission to the hospice. Moreover,
patients with a large number of inpatient days in the
30 days before enrollment in a hospice tended to
have relatively short survival after enrollment, sug-
gesting that earlier referral might indeed substitute
hospice care for more expensive hospital care. Fur-
ther work is required to clarify potential cost savings.
With respect to possible ways to modify the ob-
served survival pattern, attention should also be paid
 
Figure 2. 
 
Tukey Box Plots of the Length of Survival According to Diagnosis among 6451 Medicare Beneficiaries Enrolled in Hospice
Programs in 1990.
Box plots show the median (center vertical line), interquartile range (the 25th to the 75th percentile [box]), and “whiskers” (whiskers
are 1.5 times the interquartile range, spread out from the first and third quartiles, and do not extend beyond the smallest or largest
observed value). The diagnostic groups are arranged according to the median length of survival.
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to the fact that patients in large and for-profit hos-
pices have relatively long survival after enrollment.
Because the survival of patients after enrollment is
generally short, because evaluating newly admitted
patients is expensive, and because payment is made
on a per diem basis, these observations suggest that
such hospices may encourage the early enrollment of
patients as a way to recoup the high up-front costs
associated with admission.
 
43
 
 Do such hospices have
efficient outreach programs or place fewer barriers
to enrollment? Do they offer care in such a way that
patients, families, and physicians are willing to con-
sider earlier enrollment? Or do they inappropriately
admit patients they expect to live many months after
enrollment? Conversely, do they refuse referrals of
patients who are near death? If so, how do they iden-
tify such patients?
Our study has several limitations. First, only pa-
tients  actually  enrolled  in  hospice  programs  were
studied, and hence the timing of enrollment was ex-
amined  only  for  such  patients.  Second,  our  study
sample may not have been representative of all pa-
tients  receiving  hospice  care;  however,  Medicare
beneficiaries  account  for  about  80  percent  of  pa-
tients in hospices. Third, data on the performance
status of patients were not available, but we did ad-
just for coexisting conditions and for hospitalization
before enrollment. Fourth, using claims data to esti-
mate Charlson scores has certain unavoidable limita-
tions.
 
44,45
 
 Fifth, we did not study the duration of ill-
ness before enrollment in a hospice. Sixth, we did
not  measure  the  use  of  health  care  services  other
than inpatient hospital care, such as prescription med-
ications or home nursing care. Finally, no informa-
tion was available about the referring physicians or
about patients’ preferences.
Changes in patterns of enrollment in hospice pro-
grams  might  reduce  expenditures  for  health  care
while improving the quality of care at the end of life.
A change in enrollment patterns, however, would re-
quire  that  physicians,  patients,  and  families  accept
the provision of hospice care earlier in the course of
illness. Our findings thus suggest a need for further
investigation of the characteristics of physicians, pa-
tients, and hospice providers that are associated with
the timing of enrollment in hospice programs. Clos-
er study is needed of the process by which patients,
families, physicians, and hospice staff members de-
cide whether and when to enroll a patient in a hos-
pice program. Better understanding of this process
may  lead  to  improved  access  to  this  humane  and
cost-effective form of terminal care.
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CORRECTION
Survival of Medicare Patients after Enrollment in
Hospice Programs
Survival of Medicare Patients after Enrollment in Hospice Programs
. On page 174, in Table 1, several of the median survival values
were incorrect. The correct values are as follows: urinary tract, 34
days; colon or rectum, 34.5 days; female genital tract, 38 days; upper
gastrointestinal tract, 38 days; head or neck, 44 days; lung, 31 days;
breast, 50 days; central nervous system, 46 days; prostate, 43.5 days;
and liver or biliary tract, 24 days.
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